Aeon Biopharma, INC Form 4 insider transactions

AEON Biopharma's Chief Financial Officer, John Bencich, acquired 754,717 restricted stock units on April 2, 2026, as part of a long-term incentive plan.

AEON Biopharma's CLO, CSO, and Corporate Secretary, Alexander Blair Wilson, reported significant restricted stock unit awards, increasing his direct beneficial ownership.

AEON Biopharma's Principal Accounting Officer, Jennifer Sy, increased her beneficial ownership through significant restricted stock unit grants and modifications.

AEON Biopharma's President and CEO, Robert E. Bancroft, was granted 3,000,000 restricted stock units, vesting over four years.

AEON Biopharma, Inc. announced that Director Shelley B. Thunen was granted 308,641 Restricted Stock Units (RSUs) as part of her compensation, vesting fully on May 21, 2026.

AEON Biopharma, Inc.'s Executive Vice President, Chief Legal Officer, and Corporate Secretary, Alexander Blair Wilson, was granted 1,316,872 Restricted Stock Units as part of executive compensation.

AEON Biopharma's Chief Medical Officer, Chad Oh, was granted 1,316,872 Restricted Stock Units (RSUs) on May 21, 2025, as part of his compensation.

AEON Biopharma, Inc. has granted 925,925 Restricted Stock Units (RSUs) to its Chief Accounting Officer, Jennifer Sy, as part of her compensation package.

AEON Biopharma, Inc. Director Marc Forth was granted 370,370 Restricted Stock Units (RSUs) on May 21, 2025, as part of his compensation, aligning his interests with shareholder value.

AEON Biopharma, Inc. disclosed that Director Robert J. Palmisano was granted 308,641 Restricted Stock Units (RSUs) as part of his compensation.

AEON Biopharma, Inc. Director Eric G. Carter has been granted 308,641 Restricted Stock Units (RSUs) as part of his compensation, vesting fully on May 21, 2026.

AEON Biopharma, Inc. Director Jost Fischer was granted 308,641 Restricted Stock Units (RSUs) as part of his compensation, which will vest fully on May 21, 2026.

Jost Fischer, a Director at AEON Biopharma, Inc., has acquired 60,000 shares of Class A Common Stock, signaling increased confidence in the company.

Director Jost Fischer increased his holdings in AEON Biopharma, Inc. by purchasing shares of Class A Common Stock in two transactions on May 19 and May 20, 2025.

Robert E. Bancroft, President & CEO of Aeon Biopharma, acquired 177,103 restricted stock units (RSUs) convertible to Class A Common Stock on May 14, 2025.

Robert E. Bancroft, President & CEO of Aeon Biopharma, Inc., was granted stock options for 59,034 shares on April 29, 2025.

Robert J. Palmisano, a director at AEON Biopharma, files an amended Form 4 to correct an omission in a previous filing regarding shares held by The Palmisano Family, LLC and to report a grant of restricted stock units.

CEO Marc Forth reports acquisition of shares and options in AEON Biopharma, including restricted stock units and stock options, according to a Form 4 filing.

Alexander Blair Wilson, Executive VP, CLO & Corporate Secretary of AEON Biopharma, reports the acquisition of restricted stock units and stock options.

Director Jost Fischer reports acquisition of stock and option awards in AEON Biopharma, Inc.

Chad Oh, Chief Medical Officer of AEON Biopharma, was granted restricted stock units and stock options on August 31, 2024.

Jennifer Sy, Principal Accounting Officer of AEON Biopharma, was granted stock options and restricted stock units on August 31, 2024.

Director Eric G. Carter receives stock options and restricted stock units in AEON Biopharma, Inc.

Director Shelley B. Thunen reports acquisition of AEON Biopharma shares and stock options.

Director Robert J. Palmisano receives stock options and restricted stock units from AEON Biopharma.

Daewoong Pharmaceutical Co., Ltd. acquired a $10 million senior secured convertible note in AEON Biopharma, Inc. on April 12, 2024, which is convertible into Class A common stock under certain conditions.

Daewoong Co., Ltd. acquired a $10 million senior secured convertible note in AEON Biopharma, Inc. on April 11, 2024, which is convertible into Class A common stock under certain conditions.

Daewoong Pharmaceutical acquires a $5 million senior secured convertible note in AEON Biopharma, potentially converting into common stock upon a qualified financing event.

Director Shelley B. Thunen acquired 16,260 stock options in AEON Biopharma, Inc. on March 19, 2024.

Robert Palmisano, a director and 10% owner of AEON Biopharma, was granted stock options on March 19, 2024.